Publications by authors named "Christelle Ansaldi"

Claim this Profile
E
Ezurpimtrostat, A Palmitoyl-Protein Thioesterase-1 Inhibitor, Combined with PD-1 Inhibition Provides CD8 Lymphocyte Repopulation in Hepatocellular Carcinoma.
Eloïne Bestion, Madani Rachid, Annemilaï Tijeras-Raballand, Gael Roth, Thomas Decaens, Christelle Ansaldi

Target Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers.
James J Harding, Ahmad Awada, Gael Roth, Thomas Decaens, Philippe Merle, Christelle Ansaldi

Liver Cancer· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma modulation of lysosomal functions.
Sonia Brun, Eloïne Bestion, Eric Raymond, Firas Bassissi, Zuzana Macek Jilkova, Christelle Ansaldi

Autophagy· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective screening of liver fibrosis in a primary care cohort using systematic calculation of fib-4 in routine results.
Philippe Halfon, Christelle Ansaldi, Guillaume Penaranda, Laurent Chiche, Patrick Dukan

PLoS One· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GNS561 acts as a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-β1 inhibition.
Eloïne Bestion, Zuzana Macek Jilkova, Jean-Louis Mège, Marie Novello, Keerthi Kurma, Christelle Ansaldi

Ther Adv Chronic Dis· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinoma.
Sonia Brun, Firas Bassissi, Cindy Serdjebi, Marie Novello, Jennifer Tracz, Christelle Ansaldi

Invest New Drugs· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sofosbuvir plus ledipasvir in combination for the treatment of hepatitis C infection.
Marc Bourlière, Xavier Adhoute, Christelle Ansaldi, Valérie Oules, Souad Benali

Expert Rev Gastroenterol Hepatol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimal therapy of genotype-2 chronic hepatitis C: what's new?
Marc Bourlière, Souad Benali, Christelle Ansaldi, Gaelle Le Folgoc, Aurelie Riso

Liver Int· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sofosbuvir as backbone of interferon free treatments.
Marc Bourlière, Valèrie Oules, Christelle Ansaldi, Xavier Adhoute, Paul Castellani

Dig Liver Dis· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic hepatitis C: future treatment.
Astrid Wendt, Xavier Adhoute, Paul Castellani, Valerie Oules, Christelle Ansaldi

Clin Pharmacol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How to optimize current therapy of HCV genotype 1 infection with boceprevir.
Marc Bourlière, Xavier Adhoute, Astrid Wendt, Christelle Ansaldi, Valérie Oules

Liver Int· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Treatment of hepatitis C].
Marc Bourlière, Asma Khaloun, Paul Castellani, Isabelle Portal, Christelle Ansaldi

Rev Prat· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis